CU20210009A7 - Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) - Google Patents
Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)Info
- Publication number
- CU20210009A7 CU20210009A7 CU2021000009A CU20210009A CU20210009A7 CU 20210009 A7 CU20210009 A7 CU 20210009A7 CU 2021000009 A CU2021000009 A CU 2021000009A CU 20210009 A CU20210009 A CU 20210009A CU 20210009 A7 CU20210009 A7 CU 20210009A7
- Authority
- CU
- Cuba
- Prior art keywords
- nlrp3
- nod
- receptor protein
- inflammatory activity
- pyrolo
- Prior art date
Links
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185580 | 2018-07-25 | ||
| EP19175246 | 2019-05-17 | ||
| PCT/IB2019/056278 WO2020021447A1 (en) | 2018-07-25 | 2019-07-23 | Nlrp3 inflammasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20210009A7 true CU20210009A7 (es) | 2021-08-06 |
Family
ID=67989037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000009A CU20210009A7 (es) | 2018-07-25 | 2019-07-23 | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210308140A1 (pt) |
| EP (1) | EP3827008B1 (pt) |
| JP (1) | JP7555327B2 (pt) |
| KR (1) | KR20210038877A (pt) |
| CN (1) | CN112424207B (pt) |
| AU (1) | AU2019309727B2 (pt) |
| BR (1) | BR112021000964A2 (pt) |
| CA (1) | CA3103943A1 (pt) |
| CL (1) | CL2021000191A1 (pt) |
| CO (1) | CO2021000537A2 (pt) |
| CR (1) | CR20210045A (pt) |
| CU (1) | CU20210009A7 (pt) |
| DO (1) | DOP2021000019A (pt) |
| EC (1) | ECSP21004787A (pt) |
| IL (1) | IL280336A (pt) |
| JO (1) | JOP20210017A1 (pt) |
| MA (1) | MA53388A (pt) |
| MX (1) | MX2021000925A (pt) |
| PE (1) | PE20210406A1 (pt) |
| PH (1) | PH12021550166A1 (pt) |
| SG (1) | SG11202012321PA (pt) |
| WO (1) | WO2020021447A1 (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330054A1 (en) * | 2020-03-31 | 2023-10-19 | Olatec Therapeutics Llc | Method for preventing or treating lung infection and lung inflammation |
| AU2021255895A1 (en) | 2020-04-15 | 2022-12-15 | Janssen Pharmaceutica Nv | Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| MX2022012897A (es) | 2020-04-15 | 2022-11-14 | Janssen Pharmaceutica Nv | Pirazolo[1,5-d][1,2,4]triazin-5(4h)acetamidas como inhibidores de la ruta del inflamasoma nlrp3. |
| AU2021260115A1 (en) | 2020-04-23 | 2023-01-05 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of NLRP3 |
| JP2023523756A (ja) | 2020-04-30 | 2023-06-07 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なトリアジノインドール化合物 |
| EP4157823A1 (en) | 2020-05-28 | 2023-04-05 | JANSSEN Pharmaceutica NV | Compounds |
| MX2022014709A (es) | 2020-06-19 | 2022-12-16 | Ac Immune Sa | Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3). |
| AU2021324901A1 (en) * | 2020-08-14 | 2023-03-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| JP2023542205A (ja) | 2020-09-24 | 2023-10-05 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規化合物 |
| CN114478537B (zh) * | 2020-11-13 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 环酰胺并环化合物及其医药用途 |
| JP2024508017A (ja) | 2021-03-04 | 2024-02-21 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３を調節する４－アルコキシ－６－オキソ－ピリダジン誘導体 |
| MX2023010223A (es) | 2021-03-04 | 2023-09-11 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3. |
| CN113230240B (zh) * | 2021-03-22 | 2022-12-27 | 广州医科大学 | 1,3-二苯基丙-2-烯-1-酮衍生物及其应用 |
| CA3215235A1 (en) * | 2021-04-13 | 2022-10-20 | Sharon KLIER | Methods of treating retinal vasculopathies |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| AU2022263621A1 (en) * | 2021-04-29 | 2023-12-14 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| MX2022007854A (es) | 2021-06-23 | 2022-12-26 | Yoda Pharmaceuticals Inc | Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3. |
| EP4363418A1 (en) | 2021-07-01 | 2024-05-08 | JANSSEN Pharmaceutica NV | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| WO2023028536A1 (en) * | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| EP4401739A1 (en) * | 2021-09-17 | 2024-07-24 | Nico Therapeutics, Inc. | Compounds, compositions and methods |
| KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| IL314781A (en) * | 2022-02-21 | 2024-10-01 | Sanofi | Thianopyrrolotriazine compounds, their preparation and their therapeutic use |
| WO2024013395A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| WO2024023266A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| TW202417456A (zh) * | 2022-08-10 | 2024-05-01 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| US20240124451A1 (en) | 2022-09-23 | 2024-04-18 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2024196788A1 (en) * | 2023-03-17 | 2024-09-26 | Ventus Therapeutics U.S., Inc. | Amide derivatives for inhibiting nlrp3 and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009008906A2 (en) * | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| AU2010309788A1 (en) | 2009-10-20 | 2012-04-05 | Novartis Ag | Glycoside derivative and uses thereof |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| MY162132A (en) | 2010-06-23 | 2017-05-31 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| CN103096716B (zh) | 2010-08-10 | 2016-03-02 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐 |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| DK2718270T3 (da) | 2011-06-10 | 2022-08-01 | Merck Patent Gmbh | Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| MX353548B (es) | 2011-11-29 | 2018-01-18 | Ono Pharmaceutical Co | Clorhidrato derivado de purinona. |
| WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
| NZ630925A (en) | 2012-09-10 | 2016-10-28 | Principia Biopharma Inc | Pyrazolopyrimidine compounds as kinase inhibitors |
| MX2015006710A (es) | 2012-11-28 | 2016-01-15 | Intercept Pharmaceuticals Inc | Tratamiento de las enfermedades pulmonares. |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| MX367918B (es) | 2013-04-25 | 2019-09-11 | Beigene Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. |
| CN105682656B (zh) | 2013-11-05 | 2019-11-05 | 诺华股份有限公司 | 调节法尼醇x受体的组合物和方法 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| WO2015083008A1 (en) | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| SI3083564T1 (sl) | 2013-12-20 | 2018-10-30 | Novartis Ag | Derivati heteroarilbutanojske kisline kot inhibitorji LTA4H |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
| AU2015259403B2 (en) | 2014-05-13 | 2017-07-27 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
| CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| TN2018000218A1 (en) | 2014-10-24 | 2019-10-04 | Bristol Myers Squibb Co | Indole carboxamides compounds useful as kinase inhibitors. |
| SG11201705026UA (en) | 2014-12-24 | 2017-07-28 | Principia Biopharma Inc | Site specific dosing of a btk inhibitor |
| CA2987335A1 (en) | 2015-06-03 | 2016-12-08 | David Goldstein | Bruton tyrosine kinase inhibitors |
| WO2016201280A1 (en) | 2015-06-10 | 2016-12-15 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| CA3001744A1 (en) | 2015-10-09 | 2017-04-13 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| JP6913100B2 (ja) | 2015-11-04 | 2021-08-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法 |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| CA3009256C (en) | 2016-01-05 | 2023-08-22 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of btk kinase inhibitor and preparation method thereof |
| MX2018012249A (es) * | 2016-04-19 | 2019-02-07 | Innate Tumor Immunity Inc | Moduladores de nlpr3. |
| KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
| CN115054586B (zh) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| US11926600B2 (en) * | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
-
2019
- 2019-07-23 MA MA053388A patent/MA53388A/fr unknown
- 2019-07-23 KR KR1020217001895A patent/KR20210038877A/ko unknown
- 2019-07-23 CN CN201980047047.4A patent/CN112424207B/zh active Active
- 2019-07-23 SG SG11202012321PA patent/SG11202012321PA/en unknown
- 2019-07-23 CR CR20210045A patent/CR20210045A/es unknown
- 2019-07-23 JP JP2021503752A patent/JP7555327B2/ja active Active
- 2019-07-23 PE PE2021000092A patent/PE20210406A1/es unknown
- 2019-07-23 BR BR112021000964-7A patent/BR112021000964A2/pt not_active Application Discontinuation
- 2019-07-23 CA CA3103943A patent/CA3103943A1/en active Pending
- 2019-07-23 EP EP19769892.1A patent/EP3827008B1/en active Active
- 2019-07-23 US US17/259,252 patent/US20210308140A1/en active Pending
- 2019-07-23 WO PCT/IB2019/056278 patent/WO2020021447A1/en active Application Filing
- 2019-07-23 JO JOP/2021/0017A patent/JOP20210017A1/ar unknown
- 2019-07-23 MX MX2021000925A patent/MX2021000925A/es unknown
- 2019-07-23 CU CU2021000009A patent/CU20210009A7/es unknown
- 2019-07-23 AU AU2019309727A patent/AU2019309727B2/en not_active Ceased
-
2021
- 2021-01-21 PH PH12021550166A patent/PH12021550166A1/en unknown
- 2021-01-21 IL IL280336A patent/IL280336A/en unknown
- 2021-01-22 EC ECSENADI20214787A patent/ECSP21004787A/es unknown
- 2021-01-22 DO DO2021000019A patent/DOP2021000019A/es unknown
- 2021-01-22 CO CONC2021/0000537A patent/CO2021000537A2/es unknown
- 2021-01-22 CL CL2021000191A patent/CL2021000191A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020021447A1 (en) | 2020-01-30 |
| AU2019309727A1 (en) | 2021-01-07 |
| BR112021000964A2 (pt) | 2021-04-20 |
| AU2019309727B2 (en) | 2021-12-23 |
| CO2021000537A2 (es) | 2021-01-29 |
| PE20210406A1 (es) | 2021-03-02 |
| ECSP21004787A (es) | 2021-03-31 |
| CR20210045A (es) | 2021-06-18 |
| JP2021532124A (ja) | 2021-11-25 |
| IL280336A (en) | 2021-03-01 |
| MX2021000925A (es) | 2021-03-31 |
| EP3827008B1 (en) | 2024-07-31 |
| CL2021000191A1 (es) | 2021-08-20 |
| JP7555327B2 (ja) | 2024-09-24 |
| DOP2021000019A (es) | 2021-02-15 |
| KR20210038877A (ko) | 2021-04-08 |
| SG11202012321PA (en) | 2021-02-25 |
| US20210308140A1 (en) | 2021-10-07 |
| CN112424207B (zh) | 2024-03-19 |
| MA53388A (fr) | 2021-06-02 |
| PH12021550166A1 (en) | 2021-09-13 |
| JOP20210017A1 (ar) | 2021-01-21 |
| EP3827008A1 (en) | 2021-06-02 |
| CA3103943A1 (en) | 2020-01-30 |
| CN112424207A (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| CY1125359T1 (el) | Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5 | |
| CL2021003012A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CU24621B1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| CL2017001675A1 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| GT201600085A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| CY1122381T1 (el) | Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta | |
| CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| CY1123185T1 (el) | Παραγωγα ινδολιου |